Phase 2
N=192
Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
Hip Arthropathy
Bottom Line
View on ClinicalTrials.gov: NCT03977454 ↗Enrolled (actual)
192
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcome: Primary: Daily Opioid Consumption — 29.3; 30.8; 49.6; 51.8 milligram — p=0.69
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Nerve Block (Procedure); Periarticular Injection (PAI) (Procedure); Ropivacaine (Drug); Dex (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Daily Opioid Consumption |
29.3; 30.8; 49.6; 51.8; 62.1; 67.7 | 0.69 |
| SECONDARY Change in Pain Intensity While in Hospital |
4.9; 5.0; 4.2; 4.4; 3.9; 4.0 | 0.92 |
| SECONDARY Length of Stay |
47.2; 46.7 | 0.91 |
| SECONDARY Harris Hip Score |
— | — |
| SECONDARY Brief Pain Inventory: Interference |
6.2; 6.3; 2.8; 2.8 | 0.85 |
Summary
This study will assess if preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) with ropivacaine and glucocorticoids provide more effective analgesia than periarticular injection (PAI) with the same mixture in total hip arthroplasty (THA).
Eligibility Criteria
Inclusion Criteria
- Elective unilateral primary THA
- All surgical approaches
- American Society of Anesthesiologist (ASA) status I, II and III.
Exclusion Criteria
- Patient refusal;
- Age less than 18 years
- Those with cognitive dysfunction, psychiatric disorder, or non-English speaking patients that cannot consent or communicate clear understanding of the protocol with research team;
- Coagulopathy;
Data sourced from ClinicalTrials.gov (NCT03977454). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.